isabelobrien, Author at European Medical Journal - Page 52 of 66

Keren Leshem on running a women's health business

Keren Leshem, Chief Executive Officer, OCON Healthcare, discusses how she transformed the women’s health company’s business strategy.

How to avoid alienation during digital upskilling

To do well at digital transformation, pharma leaders must balance skills development with maintaining employee morale.

Melinta Therapeutics’s Christine Miller on being fuelled by purpose

Christine Miller is the President, Chief Executive Officer, and member of the board, Melinta Therapeutics, speaks to us about her path into the pharmaceutical industry, her mission to end antimicrobial resistance, and how to be an effective leader in pharma today

Navigating launch challenges for an improved patient journey

Amidst an ever-changing launch landscape, the COVID-19 pandemic has entirely disrupted the pharmaceutical industry, encouraging adaptation for success. By understanding the transformed patient journey, leveraging digital campaigns, and innovating in healthcare marketing strategies, how can pharma find new avenues for launch success?

A joint mission for social justice

Social justice is a rising priority for all industries, but particularly for the pharmaceutical sector in the wake of COVID-19 and the social inequities it unveiled. We look at how the industry is increasingly working alongside the world’s top advertising agencies to promote growth from good in their activities.

How can medical affairs lead the way in neurology?

Neurological conditions are complex and require a high level of expertise and sensitivity, making them an juicy area for medical affairs teams. How do the challenges shape the MA role in this space and how is the landscape evolving?

Edmond Chan on improving patient outcomes

Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haematology, Janssen, discusses the MA impact on improving patient outcomes.

What's next Mr President?

As the pharmaceutical industry transitions from the Trump to the Biden era, what regulatory changes can be expected and how will a new approach to healthcare policy affect the sector?

Ensuring access to medicine for all in LMICs

Addressing global access to medicine, particularly in LMICs, poses a significant challenge. As COVID-19 vaccines are distributed, how can the pharmaceutical industry ensure they reach vulnerable populations in these countries while protecting patent rights?

The reality of caregiving in a crisis

While the pandemic has placed pressure and strain on all members of society, it has had a profound and lesser acknowledged effect on unpaid and family carers. What has been the impact of COVID-19 on those looking after loved ones and how can we better support them in the future?